Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK).
Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK).
复制标题
DOI：
10.3390/vaccines10101601
复制
发表时间：
2022-09-23
期刊：
影响因子：
7.8
通讯作者：
Martineau AR
中科院分区：
文献类型：
--
作者：
Jolliffe DA;Faustini SE;Holt H;Perdek N;Maltby S;Talaei M;Greenig M;Vivaldi G;Tydeman F;Symons J;Davies GA;Lyons RA;Griffiths CJ;Kee F;Sheikh A;Shaheen SO;Richter AG;Martineau AR
对SARS-CoV-2疫苗的抗体反应因原因而异，原因仍然知之甚少。一系列的社会人口，行为，临床，药理学和营养因素可以解释这些差异。为了研究这一假设，我们检测了在2020年12月至2021年7月期间接种第一剂疫苗的英国成年人在2剂ChAdOx 1 nCoV-19（ChAdOx 1，阿斯利康）或BNT 162 b2（辉瑞BioNTech）之前和之后是否存在IgG、伊加和IgM（IgGAM）联合抗刺突抗体。使用系列在线问卷收集了66个潜在的社会人口学、行为学、临床、药理学和营养学决定因素对疫苗接种的血清学反应的信息。我们使用逻辑回归来估计独立变量与两次疫苗接种后血清阴性风险之间的关联的多变量调整优势比（aOR）。此外，使用线性回归估计接种后血清阳性的参与者子集中组间抗体滴度的百分比差异。在第二次疫苗接种后中位8.6周，378/9101（4.2%）例受试者中未检测到抗刺突抗体。ChAdOx 1与BNT 162 b2给药相关的接种后血清阴性风险增加（调整后的比值比（aOR）6.6，95% CI 4.2-10.4），疫苗给药之间的间隔更短（aOR 1.6，1.2-2.1，6-10 vs. >10周），一般健康状况较差vs.良好（aOR 3.1，1.4-7.0）、免疫缺陷（aOR 6.5，2.5-16.6）和免疫抑制剂使用（aOR 3.7，2.4-5.7）。对于SARS-CoV-2疫苗接种前血清阳性的参与者（aOR 0.2，0.0-0.6）和服用维生素D补充剂的参与者（aOR 0.7，0.5-0.9），血清阴性的几率较低。对疫苗接种的血清学应答与接种疫苗的时间、生活方式因素（包括吸烟、饮酒和睡眠）或使用退热药管理接种后的反应性症状无关。在8727名接种后血清学阳性个体的亚组中，ChAdOx 1与BNT 162 b2相比，（降低43.4%，41.8-44.8），第二次接种疫苗与采样之间的持续时间较长（9-16周与2-4周相比，降低12.7%，8.2-16.9），疫苗接种间隔缩短（10周降低10.4%，3.7-16.7<6 weeks vs. >），在12月至12月接种第二剂疫苗比4月至6月（低47.7%，11.4-69.1），年龄较大（年龄每增加10岁低3.3%，2.1-4.6）和高血压（低4.1%，1.1-6.9）。与南亚种族相关的较高抗体滴度（比白色种族高16.2%，3.0-31.1）或混血/多种族/其他种族（比白色种族高11.8%，2.9-21.6），体重指数较高（BMI; BMI 25-30 vs. <25 kg/m2高2.9%，0.2-5.7）和SARS-CoV-2疫苗接种前血清阳性（对于血清反应阳性并出现COVID-19症状的人，与接种前血清反应阴性的人相比，高出105.1%，94.1-116.6）。总之，我们确定了SARS-CoV-2疫苗抗体反应的多个决定因素，其中许多是可修改的。
Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly understood. A range of sociodemographic, behavioural, clinical, pharmacologic and nutritional factors could explain these differences. To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021. Information on sixty-six potential sociodemographic, behavioural, clinical, pharmacologic and nutritional determinants of serological response to vaccination was captured using serial online questionnaires. We used logistic regression to estimate multivariable-adjusted odds ratios (aORs) for associations between independent variables and risk of seronegativity following two vaccine doses. Additionally, percentage differences in antibody titres between groups were estimated in the sub-set of participants who were seropositive post-vaccination using linear regression. Anti-spike antibodies were undetectable in 378/9101 (4.2%) participants at a median of 8.6 weeks post second vaccine dose. Increased risk of post-vaccination seronegativity associated with administration of ChAdOx1 vs. BNT162b2 (adjusted odds ratio (aOR) 6.6, 95% CI 4.2–10.4), shorter interval between vaccine doses (aOR 1.6, 1.2–2.1, 6–10 vs. >10 weeks), poor vs. excellent general health (aOR 3.1, 1.4–7.0), immunodeficiency (aOR 6.5, 2.5–16.6) and immunosuppressant use (aOR 3.7, 2.4–5.7). Odds of seronegativity were lower for participants who were SARS-CoV-2 seropositive pre-vaccination (aOR 0.2, 0.0–0.6) and for those taking vitamin D supplements (aOR 0.7, 0.5–0.9). Serologic responses to vaccination did not associate with time of day of vaccine administration, lifestyle factors including tobacco smoking, alcohol intake and sleep, or use of anti-pyretics for management of reactive symptoms after vaccination. In a sub-set of 8727 individuals who were seropositive post-vaccination, lower antibody titres associated with administration of ChAdOx1 vs. BNT162b2 (43.4% lower, 41.8–44.8), longer duration between second vaccine dose and sampling (12.7% lower, 8.2–16.9, for 9–16 weeks vs. 2–4 weeks), shorter interval between vaccine doses (10.4% lower, 3.7–16.7, for <6 weeks vs. >10 weeks), receiving a second vaccine dose in October–December vs. April–June (47.7% lower, 11.4–69.1), older age (3.3% lower per 10-year increase in age, 2.1–4.6), and hypertension (4.1% lower, 1.1–6.9). Higher antibody titres associated with South Asian ethnicity (16.2% higher, 3.0–31.1, vs. White ethnicity) or Mixed/Multiple/Other ethnicity (11.8% higher, 2.9–21.6, vs. White ethnicity), higher body mass index (BMI; 2.9% higher, 0.2–5.7, for BMI 25–30 vs. <25 kg/m2) and pre-vaccination seropositivity for SARS-CoV-2 (105.1% higher, 94.1–116.6, for those seropositive and experienced COVID-19 symptoms vs. those who were seronegative pre-vaccination). In conclusion, we identify multiple determinants of antibody responses to SARS-CoV-2 vaccines, many of which are modifiable.
登录
查看更多内容
影响因子：
--
作者：
Calina D;Hartung T;Mardare I;Mitroi M;Poulas K;Tsatsakis A;Rogoveanu I;Docea AO
通讯作者：
Docea AO
影响因子：
5
作者：
Bose T;Pant N;Pinna NK;Bhar S;Dutta A;Mande SS
通讯作者：
Mande SS
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G
影响因子：
11.8
作者：
Morley GL;Taylor S;Jossi S;Perez-Toledo M;Faustini SE;Marcial-Juarez E;Shields AM;Goodall M;Allen JD;Watanabe Y;Newby ML;Crispin M;Drayson MT;Cunningham AF;Richter AG;O'Shea MK
通讯作者：
O'Shea MK
影响因子：
6.4
作者：
Martins, Cesario;Garly, May-Lill;Aaby, Peter
通讯作者：
Aaby, Peter